Back to Search Start Over

Subcutaneous or Transvenous Defibrillator Therapy

Authors :
Knops, R.E.
Nordkamp, L.R.A. Olde
Delnoy, P.H.M.
Boersma, L.V.A.
Kuschyk, J.
El-Chami, M.F.
Bonnemeier, H.
Behr, E.R.
Brouwer, T.F.
Kaab, S.
Mittal, S.
Quast, A.B.E.
Smeding, L.
Stuijt, W. van der
Weger, A. de
Wilde, K.C. de
Bijsterveld, N.R.
Richter, S.
Brouwer, M.A.
Groot, J.R. de
Kooiman, K.M.
Lambiase, P.D.
Neuzil, P.
Vernooy, K.
Alings, M.
Betts, T.R.
Bracke, F.
Burke, M.C.
Jong, J.S.S.C de
Wright, D.J.
Tijssen, J.G.
Wilde, A.A.
Knops, R.E.
Nordkamp, L.R.A. Olde
Delnoy, P.H.M.
Boersma, L.V.A.
Kuschyk, J.
El-Chami, M.F.
Bonnemeier, H.
Behr, E.R.
Brouwer, T.F.
Kaab, S.
Mittal, S.
Quast, A.B.E.
Smeding, L.
Stuijt, W. van der
Weger, A. de
Wilde, K.C. de
Bijsterveld, N.R.
Richter, S.
Brouwer, M.A.
Groot, J.R. de
Kooiman, K.M.
Lambiase, P.D.
Neuzil, P.
Vernooy, K.
Alings, M.
Betts, T.R.
Bracke, F.
Burke, M.C.
Jong, J.S.S.C de
Wright, D.J.
Tijssen, J.G.
Wilde, A.A.
Source :
The New England Journal of Medicine; 526; 536; 0028-4793; 6; vol. 383; ~The New England Journal of Medicine~526~536~~~0028-4793~6~383~~
Publication Year :
2020

Abstract

Contains fulltext : 225390.pdf (Publisher’s version ) (Open Access)<br />BACKGROUND: The subcutaneous implantable cardioverter-defibrillator (ICD) was designed to avoid complications related to the transvenous ICD lead by using an entirely extrathoracic placement. Evidence comparing these systems has been based primarily on observational studies. METHODS: We conducted a noninferiority trial in which patients with an indication for an ICD but no indication for pacing were assigned to receive a subcutaneous ICD or transvenous ICD. The primary end point was the composite of device-related complications and inappropriate shocks; the noninferiority margin for the upper boundary of the 95% confidence interval for the hazard ratio (subcutaneous ICD vs. transvenous ICD) was 1.45. A superiority analysis was prespecified if noninferiority was established. Secondary end points included death and appropriate shocks. RESULTS: A total of 849 patients (426 in the subcutaneous ICD group and 423 in the transvenous ICD group) were included in the analyses. At a median follow-up of 49.1 months, a primary end-point event occurred in 68 patients in the subcutaneous ICD group and in 68 patients in the transvenous ICD group (48-month Kaplan-Meier estimated cumulative incidence, 15.1% and 15.7%, respectively; hazard ratio, 0.99; 95% confidence interval [CI], 0.71 to 1.39; P = 0.01 for noninferiority; P = 0.95 for superiority). Device-related complications occurred in 31 patients in the subcutaneous ICD group and in 44 in the transvenous ICD group (hazard ratio, 0.69; 95% CI, 0.44 to 1.09); inappropriate shocks occurred in 41 and 29 patients, respectively (hazard ratio, 1.43; 95% CI, 0.89 to 2.30). Death occurred in 83 patients in the subcutaneous ICD group and in 68 in the transvenous ICD group (hazard ratio, 1.23; 95% CI, 0.89 to 1.70); appropriate shocks occurred in 83 and 57 patients, respectively (hazard ratio, 1.52; 95% CI, 1.08 to 2.12). CONCLUSIONS: In patients with an indication for an ICD but no indication for pacing, the subcutaneous ICD was noninferi

Details

Database :
OAIster
Journal :
The New England Journal of Medicine; 526; 536; 0028-4793; 6; vol. 383; ~The New England Journal of Medicine~526~536~~~0028-4793~6~383~~
Publication Type :
Electronic Resource
Accession number :
edsoai.on1284018721
Document Type :
Electronic Resource